China: Pharmaceutical Opportunities Chinese Pharma Firms on the Lookout for Strategic Alliances for Innovative siRNA-based Therapeutics
Since January 2020, Chinese pharma companies have entered into four deals with siRNA players to develop innovative siRNA-based therapeutics in the background of its huge potential in the pharma industry as well to enhance their pipeline portfolios. This includes Hansoh Pharma’s strategic alliance with Silence Therapeutics which is claimed to be the third biggest siRNA-based strategic alliance globally in terms of the deal's overall value (16 million dollars) since Jan 2020.
London/UK – The overall potential of Small interfering RNA (siRNA)-based therapeutics has attracted Chinese pharma companies to tap opportunities and bring promising innovative therapies across the globe. Against this backdrop, the Chinese pharma companies have increased their focus towards the siRNA pipeline through strategic alliances, finds GlobalData, a leading data and analytics company.
China pharma companies have executed four deals with siRNA players since January 2020. Hansoh Pharma has executed strategic alliances with Silence Therapeutics and OliX Pharma to develop siRNA-based therapeutics in October 2021.
Prashant Khadayate, Pharma Analyst at GlobalData, comments: “Pharma companies in China are continuously scouting for opportunities to enhance their innovative pipeline portfolio. They have forged siRNA-based strategic alliances in the past as well. However, there is an increasing trend in forging these alliances since 2020.”
According to GlobalData’s Pharma Intelligence Center, Hansoh Pharma's co-development partnership with Silence Therapeutics is the third biggest siRNA-based strategic alliance globally in terms of the deal's overall value since Jan 2020. Hansoh will make a 16-million-dollar upfront payment and Silence Therapeutics is eligible to receive up to 1.3 billion dollars in additional development, regulatory and commercial milestones.
Other high value siRNA strategic alliances include AstraZeneca’s 4.1-billion-dollar partnership with Silence Therapeutics in March 2020, followed by Alnylam Pharmaceuticals’ 2.2-billion-dollar partnership with PeptiDream in July 2021.
Overall, the siRNA landscape has received a push with increased activity from the pipeline perspective. This could be due to the expected success of Novartis inclisiran in hypercholesterolemia, with a consensus forecast of sales to reach 2.3 billion dollars in 2027 as per GlobalData’s Pharma Intelligence Center.
Khadayate concludes: “The number of high-value strategic alliances within siRNA therapeutics space has increased drastically. In recent years, an increase in deal value also denotes the potential opportunities that siRNA-based therapeutics can create for pharma companies. Moreover, it is essential to note that the high value strategic alliances recently executed by the pharma companies in the siRNA space are in the early stages of development.” Read more on how to improve multivariant production processes with AI in our recent white paper